Relief Therapeutics

Supporting patients through science and innovation

further-opportunities

Over the years, Relief Therapeutics has obtained a large number of patented indications for various peptides and proteins of natural origin. Although Relief is conscious that these experimental medicinal products might be beneficial to the patients, its limited resources prevent Relief from developing them further. These programs can be out-licensed to interested companies or organizations. Do not hesitate to contact us.

Stresscopin-related peptide for treatment of Angiogenesis
Status Preclinic
Patent EP 2 190 447 JP 5480140
Expiration Sept 2028 Sept 2028
Alpha Melanotropin for the treatment of Chronic Beryllium Disease
Status Preclinic
Patent EP 2 187 954
Expiration Sept 2028
Factsheet PDF-Small Alpha Melanotropin in Chronic Beryllium Disease
Astressin for the treatment of Excessive angiogenesis
Status Preclinic
Patent JP 5395792
Expiration Sept 2028
Defensin HNP2 for the treatment of Excessive angiogenesis
Status Preclinic
Patent JP 5491396
Expiration Sept 2028
Exorphin C for the treatment of Excessive angiogenesis
Status Preclinic
Patent JP 5385284
Expiration Sept 2028
Galanin for the treatment of Excessive angiogenesis
Status Preclinic
Patent JP 5395794
Expiration Sept 2028
Neuropeptide EI for the treatment of Excessive angiogenesis
Status Preclinic
Patent EP 2 187 901 JP 5385276
Expiration Sept 2028 Sept 2028
Renin inhibitor for the treatment of Excessive angiogenesis
Status Preclinic
Patent EP 2 187 915 JP 5384501
Expiration Sept 2028 Sept 2028
Pro-Ser-Hyp-Gly-Asp-Trp for the treatment of Excessive angiogenesis
Status Preclinic
Patent JP 5385282
Expiration Sept 2028
Acetalin-2 for the treatment of HBV infections and Tuberculosis
Status Preclinic
Patent EP 2 187 913 US 8,338,380 JP 5385281
Expiration Sept 2028 Sept 2028 Sept 2028
Peptide YY for the treatment of HBV infections
Status Preclinic
Patent US 8,193,149 JP 5385278
Expiration Sept 2028 Sept 2028
Somatostatin for the treatment of HBV infections
Status Preclinic
Patent EP 2 190 535 US 8,211,856 JP 5384502
Expiration Sept 2028 Sept 2028 Sept 2028
Urocortin for the treatment of HBV infections
Status Preclinic
Patent EP 2 187 940 JP 5385283
Expiration Sept 2028 Sept 2028
Interferon Gamma for treatment of Pulmonary Fibrosis
Status Phase II
Patent EP 1 455 813
Expiration Dec 2022
Factsheet PDF-Small Interferon Gamma in Pulmonary Fibrosis
Gonadorelin for the treatment of Tuberculosis
Status Preclinic
Patent US 8,349,805 JP 5385279
Expiration Sept 2028 Sept 2028
Octreotide for treatment of Tuberculosis
Status Preclinic
Patent EP 2 188 016 US 8,541,364 JP 5385280
Expiration Sept 2028 Sept 2028 Sept 2028
Factsheet PDF-Small Octreotide in Tuberculosis
Proadrenomedullin for the treatment of Tuberculosis
Status Preclinic
Patent JP 5385277
Expiration Sept 2028

 

Valorphin for the treatment of Tuberculosis
Status Preclinic
Patent EP 2 197 477
Expiration Sept 2028

Back

Back